Contineum Therapeutics (CTNM) Expected to Announce Earnings on Wednesday

Contineum Therapeutics (NASDAQ:CTNM) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Contineum Therapeutics to post earnings of ($0.44) per share for the quarter.

Contineum Therapeutics Trading Up 0.7 %

Shares of Contineum Therapeutics stock opened at $7.64 on Tuesday. The firm has a 50-day simple moving average of $11.43 and a two-hundred day simple moving average of $15.06. Contineum Therapeutics has a fifty-two week low of $7.04 and a fifty-two week high of $22.00.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada reissued an “outperform” rating and set a $31.00 target price on shares of Contineum Therapeutics in a research note on Thursday, January 9th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $29.25.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).